BIONXT SOLUTIONS INC. (BXT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIONXT SOLUTIONS INC. (BXT) has a cash flow conversion efficiency ratio of 0.244x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.03 Million ≈ $-2.37 Million USD) by net assets (€-8.31 Million ≈ $-9.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIONXT SOLUTIONS INC. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
BIONXT SOLUTIONS INC. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how BIONXT SOLUTIONS INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
BIONXT SOLUTIONS INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIONXT SOLUTIONS INC. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eldav-L
TA:ELDAV
|
0.022x |
|
Petrolia SE
F:0PE
|
0.038x |
|
Qingdao Hengshun Zhongsheng
SHE:300208
|
-4.160x |
|
DS Sigma Holdings Berhad
KLSE:0269
|
0.005x |
|
Averbuch Formica Center Ltd
TA:AVER
|
0.047x |
|
Botanix Pharmaceuticals Ltd
AU:BOT
|
-0.591x |
|
ML System S.A.
WAR:MLS
|
0.093x |
|
Drax Group PLC
LSE:DRX
|
0.144x |
Annual Cash Flow Conversion Efficiency for BIONXT SOLUTIONS INC. (2021–2024)
The table below shows the annual cash flow conversion efficiency of BIONXT SOLUTIONS INC. from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see BIONXT SOLUTIONS INC. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-7.86 Million ≈ $-9.19 Million |
€-3.03 Million ≈ $-3.55 Million |
0.386x | -60.55% |
| 2023-12-31 | €-5.28 Million ≈ $-6.18 Million |
€-5.17 Million ≈ $-6.04 Million |
0.978x | -35.17% |
| 2022-12-31 | €-4.13 Million ≈ $-4.83 Million |
€-6.23 Million ≈ $-7.28 Million |
1.509x | +120.72% |
| 2021-12-31 | €1.67 Million ≈ $1.95 Million |
€-12.16 Million ≈ $-14.21 Million |
-7.284x | -- |
About BIONXT SOLUTIONS INC.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheum… Read more